corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published in 2002

There are 556 items in the Healthy Skepticism Library that were published in 2002.

Page 6 of 6 pages ‹ First  < 4 5 6

HSL10528
De Joncheere K, Rietveld AH, Huttin C.
Experiences with generics
International Journal of Risk and Safety in Medicine 2002; 15:(1-2):101-109

HSL10538
McCloskey A.
The high price of prescription drugs and its impact on the elderly.
Care Manag J 2002 Spr; 3:(3):143-53

HSL10539
Kellogg FR.
Editorial
Care Management Journals 2002; 3:(3):112

HSL10540
Brown K.
The medication merry-go-round
Science 2002; 299:(5613):1646-1649

HSL10548
Hilli R, Groop T.
Generic Substitution - The proposed procedure for the presciption of pharmaceuticals in Finland
EPC--European Pharmaceutical Contractor 2002; 101-103

HSL10549
Schulman D, Wallis D, Hunsperger H.
Prescription drug Co-Promotion: 21st century dealmaking
EPC European Pharmaceutical Contractor 2002; 26-28

HSL10550
Coppin B.
A call to regulate the online sale of prescription drugs
EPC European Pharmaceutical Contractor 2002; 18-20

HSL10624
Tacco F, Taggiasco N, Broissand C.
Quality assurance in hospital pharmacies: Dispensation of thalidomide
Pharmacien Hospitalier 2002; 37:(151):219-226

HSL10632
Breggin PR.
Fluvoxamine as a cause of stimulation, mania, and aggression: A critical analysis of the FDA-approved label
Ethical Human Sciences and Services 2002; 4:(3):211-227

HSL10637
Drachenberg KJ, Proll S, Urban E, Woroniecki SR.
Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: A post-marketing surveillance study
International Review of Allergology and Clinical Immunology. 2002; 8:(4):219-223

HSL10642
Spinosi P, Ciampoli R, Turchetti M.
Did any change occurr in the NSAIDs prescription following the marketing of selective COX-2 inhibitors?
Giornale Italiano di Farmacia Clinica 2002; 16:(3):138-142

HSL10643
Horn SD.
Unintended consequences of restricting drug access
Drug Benefit Trends 2002; 14:

HSL10650
Krymchantowski AV, Irikura S, Barbosa JS, Lysia R, Tavares C, Rocha N, Moreira PF.
Headache medications in drugstores of Brazil. Profiles of orientation, recommendation and sale carried out by unskilled employees with inadequate approaches
Revista Brasileira de Medicina 2002; 59:(10-11):705-710

HSL10651
Mason RG, Donaldson D.
Lessons to be learned: A case study approach Chinese herbal nephropathy and urothelial malignancy
Journal of The Royal Society for the Promotion of Health 2002; 122:(4):266-267

HSL10654
Gallagher RM.
Methadone and spinal stimulation: Old wine in new bottles
Pain Medicine 2002; 3:(4):293
http://www.blackwell-synergy.com/rd.asp?code=PME&vol=3&page=293&goto=abstract

HSL10655
Kanemori DS.
Future packaging image
American Pharmaceutical Outsourcing 2002; 3:(4):18-22

HSL10657
Something for everyone - Patients, health care professionals and industry
Pharmaceutical Journal 2002; 269:(7228):861

HSL10659
Noferi JF, Arling ER, Dillon RL.
Counterfeit drugs: A new paradigm for security
American Pharmaceutical Review 2002; 5:(4):37

HSL10660
Dwyer P.
Drug therapy and legal liability
Australian Journal of Forensic Sciences 2002; 34:(2):45-46

HSL10661
Striking-off for Viagra sale to journalist
Pharmaceutical Journal 2002; 269:(7227):829

HSL10664
Zeidler H, Kaltwasser JP, Leonard JP, Kohlmann T, Sigmund R, Degner F, Hettich M.
Prescription and tolerability of meloxicam in day-to-day practice: Postmarketing observational cohort study of 13,307 patients in germany
Journal of Clinical Rheumatology 2002; 8:(6):305-315

HSL10665
Patient packs need attention too
Pharmaceutical Journal 2002; 269:(7226):766

HSL10666
Wechsler J.
Major changes ahead for FDA
Pharmaceutical Technology Europe 2002; 14:(11):17-20

HSL10667
Albedo A.
Battle commences on the future of EU drugs
Pharmaceutical Technology Europe 2002; 14:(11):11-13

HSL10670
Sodium oxybate/GHB approved for cataplexy
WHO Drug Information 2002; 16:(2):136

HSL10671
Alosetron hydrochloride: Restricted marketing
WHO Drug Information 2002; 16:(2):135

HSL10672
MacKay DKJ.
Prescribing cascade for non-food-producing species, and changes relating to cushing's disease [1]
Veterinary Record 2002; 151:(21):643

HSL10673
Pet medicines 'resource pack' for pharmacists
Veterinary Record 2002; 151:(21):620

HSL10674
Abraham J.
Making regulation responsive to commercial interests: Streamlining drug industry watchdogs
British Medical Journal 2002; 325:(7373):1164-1167

HSL10675
Barnes J.
Herbal therapeutics: (7) Colds
Pharmaceutical Journal 2002; 269:(7224):716

HSL10676
OTC availability shout not be endorsed yet [1]
Pharmaceutical Journal 2002; 269:(7224):711

HSL10677
Cost and compliance affect statin use
Pharmaceutical Journal 2002; 269:(7224):706

HSL10678
Dispensing glucosamine
Pharmaceutical Journal 2002; 269:(7224):705

HSL10821
Curth L.
The commercialisation of medicine in the popular press: English almanacs 1640-1700.
Seventeenth Century 2002; 17:(1):48-69

HSL11900
Goldman CR, Cutler DL.
Pharmaceutical industry support of psychiatric research and education: Ethical issues and proposed remedies.
Backlar P, Cutler DL. Ethics in community mental health care: Commonplace concerns. New York: Kluwer Academic/Plenum Publishers 2002

HSL12352
Quintaneiro T.
[The Brazilian pharmaceutical market and the North American war effort].
Estud Hist. 2002; (29):141-64

HSL13290
Lexchin J, Mintzes B.
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No
Journal of Public Policy and Marketing 2002; 21:(2):194-201
http://web.archive.org/web/20080511145449/http://www.marketingpower.com/content18627.php

HSL13304
Pecotich A, Ward SP, Song Y.
Just a Spoonful of Sugar: Patent Brand Name Effects on the Antidepressant Prescription Habits of Psychiatrists and General Practitioners
Cadeaux J, Pecotich A, Eds . Macromarketing in the Asia Pacific Century: The Proceedings of the 27th Annual Macromarketing Conference Sydney: University of New South Wales 2002

HSL13370
Schubert F.
Health technology assessment. The pharmaceutical industry perspective
Int J Technol Assess Health Care. 2002 Spring; 18:(2):184-91
http://www.ncbi.nlm.nih.gov/pubmed/12053418

HSL16342
Healy D
The Creation of Psychopharmacology. Cambridge: Harvard University Press 2002
http://books.google.com.au/books?id=6O2rPJnyhj0C&dq=Healy,+David.+The+Creation+of+Psychopharmacology.&printsec=frontcover&source=bn&hl=en&ei=MJyYSti2EJjQ6gOa4ODnBA&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false

HSL17904
Ed.
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ 2002; 324:(7349):1287
http://www.bmj.com/cgi/content/extract/324/7349/1287

HSL17985
Mavroforou A, Michalodimitrakis E
Legal aspects related to marketing and use of medicinal products in Greece.
Med Law. 2002; 21:(1):1-10
http://www.ncbi.nlm.nih.gov/pubmed/12017435

HSL19052
Schwartz LM, Woloshin S.
Marketing medicine to the public: a reader's guide.
JAMA 2002 13; 287:(6):774-5
http://jama.ama-assn.org/content/287/6/774.long

HSL19392
Azoulay P
Do pharmaceutical sales respond to scientific evidence?
J Econ Manage Str 2002; 11:551–594
http://ideas.repec.org/a/bla/jemstr/v11y2002i4p551-594.html

HSL19743
Pieters T.
About media, audiences and marketing medicines: the interferons.
Clio Med 2002; 66:229-43:
http://www.ncbi.nlm.nih.gov/pubmed/12028679

HSL19744
Jones J
Medical Publishing: Part 3
PMLive.com 2002

HSL19750
Rosenberg CE.
The tyranny of diagnosis: specific entities and individual experience.
Milbank Q 2002; 80:(2):237-60
http://onlinelibrary.wiley.com/doi/10.1111/1468-0009.t01-1-00003/abstract;jsessionid=5B9815EFE8B821B590EAA5D146EE29DB.d01t02?systemMessage=Wiley+Online+Library+will+be+disrupted+14+Jan+from+10-12+GMT+for+monthly+maintenance

HSL19756
Starcevic V.
Opportunistic 'Rediscovery' of mental disorders by the pharmaceutical industry.
Psychother Psychosom 2002; 71:(6):305-10
http://content.karger.com/produktedb/produkte.asp?DOI=65989&typ=pdf

HSL19779
Wolfsthal SD, Beasley BW, Kopelman R, Stickley W, Gabryel T, Kahn MJ; Membership Survey and Scientific Data Committee, The Association of Program Directors of Internal Medicine.
Benchmarks of support in internal medicine residency training programs.
Acad Med 2002; 77:(1):50-6
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=PWVKtY1YDSjYJptRs49jD2dLTnsMb4S3HdnYYvvfJLdw2hQRJG1H!-1165837873!181195629!8091!-1?issn=1040-2446&volume=77&issue=1&spage=50

HSL19833
Abraham J.
Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK.
Soc Sci Med 2002; 55:(9):1671-90
http://linkinghub.elsevier.com/retrieve/pii/S0277953602001600

HSL19854
Pharmaceutical sponsorship of practice newsletters called into question
Medical Forum 2002 Dec10

Page 6 of 6 pages ‹ First  < 4 5 6

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







As an advertising man, I can assure you that advertising which does not work does not continue to run. If experience did not show beyond doubt that the great majority of doctors are splendidly responsive to current [prescription drug] advertising, new techniques would be devised in short order. And if, indeed, candor, accuracy, scientific completeness, and a permanent ban on cartoons came to be essential for the successful promotion of [prescription] drugs, advertising would have no choice but to comply.
- Pierre R. Garai (advertising executive) 1963